MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment
SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility
White arrow breaking the wall and passing to the other side.
MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma
MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma